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Corticosensitivity in¯ uences the degree and the duration of an in¯ ammatory reaction by
alte ring target cell response s to endogenous and/or exogenous glucocorticoid s. Indeed,
different clinical response s to glucocorticoid s have been observed among patients with
Crohn’ s disease , sugge sting different degrees of corticosensitivity in these subje cts. The
purpose of this study was to compare the corticosensitivity of patients with quie scent Crohn’ s
disease to that of healthy subje cts (HS). Nine teen patients with quie scent Crohn’ s disease and
14 HS were studied; all patients were steroid-free for at least six months; 7 of the 19 were
corticoste roid-dependent (CSD) and treated with nonglucocorticoid immunosuppressants at
the time of the study. Corticosensitivity was measured by the inhibition of LPS-induced




M) of dexamethasone . Tumor-ne crosis factor- a (TNF-a ), interleukin-6 (IL-6), and
interleukin-1 b (IL-1 b ) were measured using speci® c immunoassays. Crohn’ s disease patients
had a markedly decreased dexamethasone -mediated inhibition of TNF- a (P , 0.01) , IL-6
(P , 0.001) , and IL-1 b (P , 0.01) compared to healthy subje cts, with a shift of the
dexamethasone dose ± response curve to the right. No signi® cant differences in the basal and
LPS-stimulate d secretion of the three cytokine s were obse rved between CSD and non-CSD
patients, and both subgroups of patients had similar degrees of dexamethasone -mediated
cytokine inhibition. We conclude that patients with Crohn’ s disease have a signi® cant
decrease in the corticosensitivity of the ir leukocyte s. This may be related to a speci® c
genetic/constitutional background and/or could be acquire d, due to in¯ ammation-re lated
endocrine and/or immune factors.
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Increasing evidence supports an important role of the
hypothalamic± pituitary± adrenal (HPA) axis in the
pathoge nesis and course of in¯ ammatory diseases (1).
The end-effector of the HPA axis, glucocorticoids ,
restrain the immune and in¯ ammatory responses (2,
3). Thus, the in¯ ammatory response of in¯ ammatory
disease-susceptible Lewis and -resistant Fischer rats is
inversely related to the magnitude of the ir HPA axis
response to in¯ ammatory mediators (4, 5), while the
glucocorticoid receptor antagonist RU 486 renders
Fischer rats susceptible to streptococcus cell wall-
induced arthritis (4).
Glucocorticoids are used as ® rst line antiin¯ amma-
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tory and immunosuppre ssive drugs in many in¯ am-
matory and autoimmune diseases (6). Different clin-
ical response s to glucocorticoids have been observed
among patients suffering from such diseases, and pa-
tients with Crohn’ s disease have been classi® ed as
corticosteroid-sensitive (when a good response to
treatment is obse rved) , corticoste roid-dependent
(CSD) (when glucocorticoids are needed to keep the
in¯ ammatory disease quie scent), and corticoste roid-
resistant (CSR) (when they are not responsive to
glucocorticoid treatment). The prevalence of cortico-
steroid dependency in Crohn’ s disease is about 15±
35% (7± 9), while corticosteroid resistance is observed
in less than 10% of the patients (9, 10).
Corticosensitivity depends not only on the glu-
cocorticoid receptor (GR) number and af® nity, but
also on pre- and postreceptor mechanisms of GR
activation, including the inte ractions of GR with cy-
toplasmic and nuclear factors and speci® c DNA-
responsive elements (11, 12) . Only a few clinical stud-
ies have been carried out on corticosensitivity and
none in Crohn’ s disease . Familial glucocorticoid re-
sistance was studied by Chrousos et al (13) and Lam-
berts et al (14) and was shown to be of genetic
etiology and related to a decrease of GR af® nity for
its ligand or to a decrease in GR number per cell (13,
14) . Sher et al (15) described two populations of
corticosteroid-re sistant (CSR) asthma patients: type 1
is de ® ned by decreased GR af® nity binding, and type
2 is de ® ned by decreased GR number per cell. Type 1
CSR asthma was shown to be reversible and second-
ary to in¯ ammation, while type 2 CSR asthma ap-
peared to be genetically and/or constitutionally deter-
mined (15) . Finally, Schlaghe cke et al reported a 50%
decrease of GR number/cell in patients with rheuma-
toid arthritis (16) ; however, inexplicably, this did not
appear to in¯ uence the in vitro corticosensitivity of
these patients (17).
Whole blood cell culture is an appropriate ex vivo
technique to analyze corticosensitivity within a con-
trolled environment, by studying the inhibition of
cytokine secretion by graded concentrations of glu-
cocorticoids (18) . The aim of this work was to com-
pare corticosensitivity between patients with quie s-
cent Crohn’ s disease and healthy control subjects.
MATERIALS AND METHODS
Patients and Con trols. Patients with Crohn’s disease (10
women and 9 men) and healthy volunteers (7 women and 7
men) served as blood donors. The mean age was 35 years in
patients with Crohn’s disease (range : 20 ± 53 years) and 33
years in controls (range: 24 ± 44 years). The clinical charac-
teristics of patients with Crohn’s disease are summarized in
Table 1. All patients with quiescent Crohn’s disease were
followed in the Gastroenterology Division at the University
Hospital of LieÁ ge , Belgium. The diagnosis of Crohn’s dis-
ease was made by classical clinical, radiological, and endo-
scopic criteria. Seven of the 19 patients were corticosteroid-
dependent. The corticosteroid dependency was de® ned
either by two successive relapses following glucocorticoid
discontinuation or by two successive relapses at dose taper-
ing afte r a successful treatment of a ¯ are-up with glucocor-
ticoids (7, 8, 19) . Treatment with immunosuppressive drugs
(azathioprine or methotrexate ) allowed the complete with-
drawal of glucocorticoids in these patients. Nine non-CSD
patients were treated with 5-aminosalicylic acid (5-ASA).
All patients studied were in clinical remission and cortico-
steroid-free for at least six months. Three groups were
de® ned: non-corticosteroid-dependent (non-CSD) patients;
corticosteroid-dependent (CSD) patients; and healthy con-
trols (HS). Data from the interleukin-1b (IL-1 b ) assay of
four CSD patients and two non-CSD patients were not
included. Similarly, data from the tumor necrosis factor- a
(TNF-a ) assay of one CSD patient and one non-CSD
patient were not included because of absence of stimulation
by LPS.
Whole Blood Cell Cultures. The blood was treated as
previously described (18) . Blood samples were collected in
apyrogenic heparinized tubes provided by Biosource/
Medgenix (Fleurus, Belgium). The white blood cell count
was in the normal range in CD patients. The blood was
processed immediate ly and diluted with 1/10 RPMI 1640
supplemented with 2 mM glutamine, 100 IU/ml penicillin,
100 m g/ml streptomycin (Biowitthaker), and was then dis-
tributed in 2-ml wells. RPMI 1640 medium was tested for
apyrogenicity. LPS (endotoxin from Salmonella enteritidis;
Sigma, St. Louis, Missouri) was added at a ® nal concentra-
tion of 25 pg/ml. A synthetic glucocorticoid, dexame tha-
TABLE 1. CLINICAL CHARACTERISTICS OF CORTICOSTEROID -
DEPENDENT (CSD) AND NON-CORTICOSTEROID -DEPENDENT





Mean age [yr (range) ] 37(20± 53) 31(24± 48)
Female /male 6/6 4/3
Disease duration [months
(mean, range) ] 144(8± 284) 96(30± 156)
Crohn’s disease activity
index , 150 , 150
Disease location
Small bowel only 2/12 0/7
Colonic only 1/2 5/7
Ileocolonic 9/12 2/7
Disease type






(2 mg/kg/day) 0/12 6/7
Methotrexate
(25 mg/week) 0/12 1/7
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M in separate wells. Plates were incubated at 37°C
in a 5% CO2 athmosphere; the incubation time was 24 hr
for LPS-stimulated whole blood cell cultures (18, 20). The
contents of the wells were then collected and centrifuged at
900g for 10 minutes. Supernatants were recovered and
frozen at 2 20°C. Blood was drawn from women during the
proliferative phase of their cycle.
Immunoassays. TNF-a , IL-1 b , and IL-6 were measured
with speci® c immunoassays from Biosource/Medgenix with-
out any cross-reactivity. Immunoassays were performed ac-
cording to the manufacturer’s directions. The detection
limit was 3 pg/ml for TNF-a , 2 pg/ml for IL-1 b , and 2 pg/ml
for IL-6. Plates were read at 460 nm by a microplate ELISA
reader from Medgenix Diagnostics. Absorbancy was trans-
formed to cytokine concentration using a standard curve
computed by Medgenix ELISA software. Plasma cortisol
(RIA, Immunotech, Marseille, France) and cortisol-binding
globulin (RIA, Radim, Liege, Belgium) were measured
with the routine laboratory methods. The blood was col-
lected from each individual between 3 and 6 PM. The blood
was then processed immediately for whole blood cell cul-
tures. Plasma obtained at the same time was frozen at
2 20°C until assay. Once all the plasma samples from the
patients and the healthy subjects were collected, cortisol
and cortisol binding globulin concentrations were measured
in a single batch.
Statis tical Analyses. Statistical analyses were carried out
using the SAS software package (SAS Institute Inc., Cary,
North Carolina). The relative changes in cytokine produc-
tion were computed for each dose of dexamethasone. A log
transformation was used for both the absolute values of
cytokine production and for the percentage of the response
in each individual to normalize the distribution of the data.
A generalized linear mixed model with random effects (SAS
Proc Mixed) was ® tted to study the dexamethasone general
effect and dose effect on cytokine secretion. All results were
considered to be signi® cant at the 5% critical level (P ,
0.05). The SAS Proc Mixed is an ANOVA for repeated
measures, as is appropriate where the observations in the
same subject are not independent of each other. This
method adjusts the standard error as a function of the
covariance structure of the observations.
The ED50 was calculated as the dose of dexame thasone
necessary to produce a 50% inhibition in the secretion of
each of the three cytokines for each individual, using the
SAS Proc Mixed program. The statistical comparisons were
between the means of the ED50s in the three groups of
subjects with the Kruskal-Wallis and the Wilcoxon tests.
Other statistical comparisons within the same group or
between the three groups were performed using nonpara-
metric (Kruskal-Wallis and Wilcoxon tests) and parametric
tests (ANOVA and Student t tests afte r a logarithmic
transformation).
RESULTS
Cytokin e Secretion in Whole Blood Secretion from
CD Patien ts and Healthy Subjects
There was a signi® cant difference in cytokine secre-
tion between basal and LPS-induced leve ls of cyto-
kine s in the non-CSD patients (P , 0.001 for TNF- a ,
IL-6, and IL-1 b ), in CSD patients (P , 0.001 for
TNF-a and IL-6, P , 0.01 for IL-1 b ), and in healthy
subje cts (P , 0.001 for TNF-a , IL-6, and IL-1 b )
(Table 2).
Basal cytokine leve ls in whole blood cell culture s
were similar in both groups of patients with Crohn’ s
disease and healthy subjects. LPS-stimulated IL-6 and
TNF-a leve ls were signi® cantly different between CD
patients and healthy subje cts (P , 0.05 and P , 0.05,
respective ly) and between CSD patients and healthy
subje cts (P , 0.05 and P , 0.05, respectively) . No
difference was obse rved between non-CSD patients
and healthy subjects (Table 2).
Inh ibition of Cytokin e Secretion by Dexamethasone
in Whole Blood Cell Cultures from CD Patients
and Healthy Subjects
The results of the concentration-de pendent effect
of dexamethasone on TNF-a , IL-6, and IL-1 b secre-
tion in whole blood cell culture s in the three groups
are shown in Figure s 1± 3. In the top pane ls of these
® gure s, the mean percentages of inhibition of cyto-
kine production are presented, while in the bottom
panels the means of the logarithm ically transformed
absolute cytokine leve ls are shown.
TABLE 2. BASAL AND LPS-STIMULATED CYTOKINE LEVELS IN CORTICOSTEROID -DEPENDENT (CSD) AND
NON-CORTICOSTEROID -DEPENDENT (NON-CSD) PATIENTS WITH CROHN’S DISEASE AND HEALTHY
SUBJECTS*
Cytokine (pg/m l)
Non-CSD patients CSD patients Healthy subjects
TNF- a basal 60 6 24 (N 5 11) 104 6 84 (N 5 6) 35 6 11 (N 5 14)
TNF- a after LPS 204 6 65 (N 5 11) 248 6 160 (N 5 6)a 420 6 123 (N 5 14)
IL-6 basal 188 6 56 (N 5 12) 344 6 260 (N 5 7) 102 6 42 (N 5 14)
IL-6 after LPS 417 6 106 (N 5 12) 658 6 447 (N 5 7)a 815 6 178 (N 5 14)
IL-1 b basal 42 6 13 (N 5 10) 122 6 98 (N 5 3) 17 6 7 (N 5 14)
IL-1 b after LPS 87 6 23 (N 5 10) 167 6 124 (N 5 3) 135 6 33 (N 5 14)
* Data expressed as mean 6 SEM. CSD patients vs HS: a P , 0.05.
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TNF- a . There was a signi® cant inhibition of TNF- a





healthy subjects (P , 0.001) , in non-CSD patients
(P , 0.001) , and in CSD patients (P , 0.001). While
there was a signi® cant inhibition of TNF- a secretion
by dexamethasone at 10
2 9
M in healthy subje cts (P ,
0.001) , no inhibition was observed in non-CSD or
CSD patients.
IL-6. There was a signi® cant inhibition of IL-6





healthy subje cts (P , 0.001) and in non-CSD (P ,
001) and in CSD patients (P , 0.001) . While there
was a signi® cant inhibition of IL-6 secretion by dexa-
methasone at 10
2 9
M in healthy subje cts (P , 0.001) ,
no inhibition was observed in non-CSD or CSD pa-
tients.
IL-1 b . There was a signi® cant inhibition of IL-1 b





healthy subje cts (P , 0.001) and in non-CSD (from
P , 0.01 to P , 0.001) and in CSD patients (from P ,
0.06 to P , 0.001) . While there was a signi® cant
inhibition of IL-1 b secretion by dexamethasone at
10
2 9
M in healthy subje cts (P , 0.05) , no inhibition
was observed in non-CSD or CSD patients.
Plasma Cortisol and Cortisol-Bin ding Globu lin
Levels in CD Patien ts and Healthy Subjects
Plasma cortisol (112.6 6 6.5 vs 120.6 6 12.2 m g/dl,
respective ly) and cortisol-binding globulin (28.1 6 1.3
vs 25 6 1.3 m g/ml, respective ly) leve ls were similar
in CD patients and healthy subje cts. Plasma cor-
tisol (120 6 10.1 vs 104.5 6 7.5 m g/dl, respective ly)
and cortisol-binding globulin (25.3 6 2.0 vs 31.3 6
2.8 m g/ml) were also similar in non-CSD and CSD
patients.
Fig 1. Effect of dexame thasone on LPS-induced TNF- a secretion in
whole blood cell cultures from 17 patients with Crohn’s disease (11
non-CSD and 6 CSD) and 14 HS. Statistical analyses are described
in Results. Data are expressed as the mean 6 SEM: inhibition is
presented as mean percent base line (A, top pane l) or in mean of
logarithmically transformed absolute cytokine levels (B, bottom
pane l). HS: healthy subjects; CSD: corticosteroid-dependent; Non-
CSD: non-corticosteroid-dependent. CD patients vs HS: *P , 0.05,
**P , 0.01.
Fig 2. Effect of dexamethasone on LPS-induced IL-6 secretion in
whole blood ce ll cultures from 19 CD patients (12 non-CSD and 7
CSD) and 14 healthy subjects. Statistical analyse s are described in
Results. Data are expressed as the mean 6 SEM: inhibition is
presented as mean percent base line (A, top pane l) or in mean of
logarithmically transformed absolute cytokine levels (B, bottom
pane l). HS: healthy subjects; CSD: corticosteroid-dependent; Non-
CSD: non corticosteroid-dependent. CD patients vs HS: *P , 0.01,
**P , 0.001.
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Assessment of Corticosensitivity in CD Patien ts
and Healthy Subjects
The top pane ls of Figures 1± 3 show the mean
percentage of inhibition of cytokine production by
dexamethasone in the three groups, taking into ac-
count the O-dexamethasone concentration (cytokine
leve l after LPS stimulation) , which is the reference
for each individual (Figure s 1A, 2A, and 3A).
TNF- a . A signi® cant difference between all pa-
tients with Crohn’ s disease and controls was observed
in the general pattern of TNF-a inhibition by dexa-
methasone (P , 0.01) . A signi® cant difference also
was observed between all patients and controls in the
rate of TNF-a inhibition by dexamethasone at 1 nM
(P , 0.05) , 10 nM (P , 0.01) and 100 nM (P , 0.05) .
There was a slight, but nonsigni® cant, difference at 1
m M of dexamethasone between all patients and con-
trols (P , 0.052) (Figure 1A).
A difference was obse rved in the rate of TNF- a
inhibition between non-CSD patients and controls by
dexamethasone at 1 nM and 10 nM (P , 0.01) . A
similar difference was observed in the rate of TNF- a
inhibition between CSD patients and controls by
dexamethasone at 1 nM and 10 nM (P , 0.01) and
from 100 nM to 1 m M (P , 0.05) (Figure 1A).
IL-6. A signi® cant difference between all patients
and controls was observed in the general patte rn of
IL-6 inhibition by dexamethasone (P , 0.001) . A
signi® cant difference in IL-6 inhibition also was ob-
served between all patients and controls at 1 nM (P ,
0.01) and from 10 nM to 1 m M of dexamethasone
(P , 0.001) (Figure 2A).
There was a difference in the rate of IL-6 between
non-CSD patients and controls by dexamethasone at
1 nM (P , 0.01) and from 10 nM to 1 m M (P ,
0.001) . A difference also was obse rved between CSD
patients and controls by dexamethasone at 1 nM (P ,
0.05) and from 10 nM to 1 m M (P , 0.001) (Figure
2A).
IL-1 b . A signi® cant difference between all patients
with Crohn’ s disease and controls was obse rved in the
general patte rn of IL-1 b inhibition by dexamethasone
(P , 0.01) . A difference between all patients and
controls also was observed in the rate of IL-1 b inhi-
bition by dexamethasone at 10 nM (P , 0.01) and at
100 nM (P , 0.05) . There was a slight, but nonsignif-
icant, difference at 1 nM between all patients and
controls (P 5 0.092) (Figure 3A).
A signi® cant difference in the rate of IL-1 b inhibi-
tion was obse rved between non-CSD patients and
controls by dexamethasone at 10 nM (P , 0.01) .
There was a signi® cant difference in the rate of IL-1 b
inhibition by dexamethasone between CSD patients
and controls at 10 nM (P , 0.01) and at 1 m M (P ,
0.05) . There was a slight, but nonsigni® cant, differ-
ence at 1 nM of dexamethasone between non-CSD
patients and CSD patients versus controls (P 5 0.15
and P 5 0.16, respective ly) (Figure 3A).
Interestingly, no signi® cant diffe rence between
non-CSD and CSD patients was obse rved in the dexa-
methasone general and dose effect on cytokine secre-
tion (Figure s 1A, 2A, and 3A).
The IC50s of dexamethasone effects on the secre-
tion of the three in¯ ammatory cytokine s are reported
on Table 3. There was a global signi® cance between
patients with Crohn’ s disease and HS for TNF- a (P ,
0.01) , IL-1 b (P , 0.01) , and IL-6 (P , 0.001) . There
were no signi® cant differences between non-CSD
patients and CSD patients for each of the three
cytokine s.
Fig 3. Effect of dexamethasone on LPS-induced IL-1 b secretion in
whole blood ce ll cultures from 13 CD patients (10 non-CSD and
3-CSD) and 14 healthy subjects. Statistical analyse s are described
in Results. Data are expressed as the mean 6 SEM: inhibition is
presented as mean percent base line (A, top pane l) or in mean of
logarithmically transformed absolute cytokine levels (B, bottom
pane l). HS: healthy subjects; CSD: corticosteroid-dependent; Non-
CSD: non corticosteroid-dependent. CD patients vs HS: *P , 0.05,
**P , 0.01.
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The bottom panels of Figures 1± 3 show the means
of logarithmically transformed absolute cytokine lev-
els in the three groups. A shift to the right of the
sigmoidal dose ± response curve of cytokine inhibition
by dexamethasone was obse rved in Crohn’ s disease
patients in comparison to healthy subjects (Figure s
1B, 2B, and 3B).
There was no signi® cant difference in the inhibition
of TNF-a secretion by dexamethasone between CD
patients and healthy subjects or between the three
groups (Figure 1B). There was a signi® cant difference
in the inhibition of IL-6 secretion by dexamethasone
at 100 nM and 1 m M between CD patients and
healthy subje cts (P , 0.01 and P , 0.01, respectively) .
A signi® cant difference in the inhibition of IL-6 se-
cretion also was observed at 1 m M of dexamethasone
between non-CSD and healthy subje cts and between
CSD patients and healthy subje cts (P , 0.01) (Figure
2B). There was a signi® cant difference in the inhibi-
tion of IL-1 b secretion by dexamethasone at 100 nM
and 1 m M between CD patients and healthy subje cts
(P , 0.01 and P , 0.01, respectively) . A signi® cant
difference also was obse rved at 100 nM and 1 m M
between CSD patients and healthy subje cts (P , 0.05
and P , 0.01, respective ly) (Figure 3B).
DISCUSSION
The corticosensitivity of patients with Crohn’ s dis-
ease and control subje cts was evaluate d in this study
by the degree of inhibition of cytokine secretion in
whole blood cell cultures by graded concentrations of
dexamethasone . The data suggested a signi® cant de-
crease in the corticosensitivity of patients with
Crohn’ s disease . There was no difference between
CSD patients and non-CSD patients, however. All of
our patients in this study were in clinical remission
(Crohn’ s disease activity index , 150) and corticoste -
roid-free for at least six months. Previous studie s on
steroid-sensitive and steroid-re sistant asthma were
carried out in patients concurrently receiving glu-
cocorticoid therapy (15, 21, 22) . Glucocorticoids nor-
mally induce a down-regulation of GR, and this could
lead to a decrease in corticosensitivity. Thus, a study
of corticosensitivity in patients treated with exoge -
nous glucocorticoid s may re¯ ect treatment rathe r
than disease effect. The comple te abstention from
glucocorticoid s for at least six months in non-CSD
patients and in CSD patients treated with immuno-
suppressants allowed us to avoid this potential pitfall.
Interleukin-1 b , IL-6, and TNF-a are important cy-
tokines of innate immunity and mediate both speci® c
and nonspe ci® c in¯ ammatory response s. These cyto-
kine s are also important mediators of in¯ ammation in
the inte stinal mucosa of patients with in¯ ammatory
bowe l diseases. Enhanced secretion of such cytokine s
by periphe ral blood mononucle ar cells (PBMCs) was
reported in patients with Crohn’ s disease earlie r (23) .
We did not con® rm this, but rathe r demonstrated that
the basal production of in¯ ammatory cytokine s ex
vivo was not different from that of controls and that
after LPS stimulation, the production of TNF- a and
IL-6 was, in fact, decreased in CSD patients com-
pared to those of healthy subje cts. This could be
explaine d by the different methodologie s used and
the type of subje ct populations studied. All the CSD
patients were treated with immunosuppre ssants.
The decreased PBMC corticosensitivity of patients
with Crohn’ s disease might be related to the in¯ am-
matory state itse lf. Indeed, corticosensitivity was ear-
lie r shown to be modulate d by cytokine s (24) . Some
proin¯ ammatory cytokine s, such as IL-1 b , IL-6,
TNF-a and interferon- g (IFN- g ), increased (24 ± 26) ,
while other mostly antiin¯ ammatory cytokine s, such
as IL-4 and IL-13, decreased sensitivity to glucocor-
ticoids, possibly glucocorticoid receptor number and
af® nity changes (27, 28) . Glucocorticoids are potent
inhibitors of NF-k B, a pivotal transcription factor for
the expression of many cytokine genes in chronic
in¯ ammatory diseases (29, 30) . NF- k B functions as an
intrace llular ampli® cation factor that exacerbate s
chronic in¯ ammatory processes and itse lf inhibits the
activity of the ligand-bound glucocorticoid receptor
(31) . Excessive NF-k B induction thus could prevent
glucocorticoid suppre ssion and could contribute to a
decrease in corticosensitivity (32) .
The susceptibility to deve lop an in¯ ammatory dis-
ease could also be related to a genetically and/or
constitutionally determined decrease in corticosensi-
tivity. Type 2 CSR asthma was shown to be related to
a primary decrease of GR number per cell (15) .
TABLE 3. COMPARISON OF IC50 OF DEXAMETHASONE INHIBITION
ON THREE PROINFLAMMATORY CYTOKINES BETWEEN
CORTICOSTEROID -DEPENDENT (CSD) AND NON-CORTICOSTEROID -















TNF- a 8 6 6.5a 6.3 6 2.3a 2.7 6 2.4
IL-6 54 6 138.4b 25.4 6 28.9a 2.9 6 2.6
IL-1 b 12.2 6 17.8a 17.2 6 19.4a 2.7 6 2.3
* Data are expressed as mean 6 SD. a P , 0.001; b P , 0.001 vs
healthy subjects.
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Hyposensitivity could lead to an hype rimmune state
and to susceptibility to in¯ ammatory and autoim-
mune diseases (11, 12) . A primary decrease in corti-
cosensitivity could result in a relative inability of
endogenous glucocorticoids to modulate the mucosal
immune response to bacte rial or alimentary luminal
antige ns, superantige ns, and nonspe ci® c immuno-
stimulants. This study sugge sts that decreased corti-
cosensitivity in patients with quiescent Crohn’ s dis-
ease might be a factor favoring further relapse s.
A potential effect of the treatment with 5-ASA or
azathioprine could not be excluded. Whether such a
treatment could directly in¯ uence corticosensitivity is,
however, unclear. The patte rn and degree of dexa-
methasone -mediated inhibition were the same in qui-
escent CSD and quie scent non-CSD patients. On one
hand, this could mean that corticoste roid dependency
in Crohn’ s disease is not related to a decrease of
corticosensitivity. On the other hand, the same corti-
cosensitivity in both groups might be due to the
immunosuppressants improving the corticosensitivity
of CSD patients with Crohn’ s disease (33) .
Recently, the activity of the HPA axis itse lf was
shown to be alte red in in¯ ammatory diseases such as
rheumatoid arthritis (34) . Chikanza et al reported
that rheumatoid arthritis patients had normal cortisol
leve ls and a normal response to exogenous cortico-
tropin releasing factor but a reduced response to
increased leve ls of circulating IL-1 and IL-6 induced
by surgical stress, compared to patients with osteoar-
thritis and chronic osteomyelitis also undergoing a
major operation (34) . Similarly, early untreated pa-
tients with rheumatoid arthritis had paradoxically
normal ACTH and cortisol levels, which would not
have been predicted by the ir pain, fever, and high
leve ls of in¯ ammatory cytokine s (35) . In our patients,
hypercortisolism could be associated with a decrease
in corticosensitivity via homologous down-regulation
of the GR. The HPA axis of patients with Crohn’ s
disease has not been studied extensive ly as yet; how-
ever, our normal base line measurements of cortisol
and cortisol-binding globulin in this study do not
corroborate the idea of a major change in the activity
of the HPA axis in Crohn’ s disease, yet further studie s
need to be done to rule out subtle or dynamic change s
of the ir axis.
In conclusion, a decrease of corticosensitivity in
whole blood cell culture s was obse rved in patients
with Crohn’ s disease compared to healthy controls.
The alte ration of corticosensitivity in Crohn’ s disease
could be genetic/constitutional and/or acquired in
response to endocrine and/or immune factors related
to the in¯ ammatory disease . Furthe r studie s are
needed to characterize the complex inte ractions be-
tween the HPA axis and the immune system in in-
¯ ammatory bowe l diseases.
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